Appendix cancer differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 486: | Line 486: | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup> | | colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | Periumbelical, RLQ | ||
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki> | | style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki> | ||
| style="background: #F5F5F5; padding: 5px;" | +/- Diarrhea | | style="background: #F5F5F5; padding: 5px;" | +/- Diarrhea | ||
Line 533: | Line 533: | ||
<sup>3</sup> Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer. | <sup>3</sup> Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer. | ||
<nowiki>*</nowiki>'''Abbreviations:''' RLQ: Right Lower Quadrant, AFP:Alpha Fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA 125: Cancer antigen 125 | |||
==References== | ==References== |
Revision as of 20:54, 14 February 2019
Appendix cancer Microchapters |
Diagnosis |
---|
Treatment |
Appendix cancer differential diagnosis On the Web |
American Roentgen Ray Society Images of Appendix cancer differential diagnosis |
Risk calculators and risk factors for Appendix cancer differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
Differentiating appendix cancer from other Diseases
- Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
- As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype.
- Carcinoid tumors must be differentiated from other diseases that causecarcinoid syndrome, such as palpitation, facial flushing, diarrhea, .
- In contrast, adenocarcinomas and cystadenocarcinomas must be differentiated from other diseases that cause acute appendicitis or present with pseudomyxoma peritonei, such as colorectal cancers, appendix mucoceles.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||
Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other diagnostic studies and imaging modalities | ||||
Appendix cancer | Adenocarcinoma1 | +/- | -/+ | Constipation |
|
- | - |
|
- |
|
|
|
|
Positron emission tomography (PET) | Gross pathology:
Microscopic pathology:
IHC might be positive for the following stains:
|
Biopsy |
Carcinoid tumor2 | +/- | - | Diarrhea |
|
- | - |
|
+ |
|
|
Gross pathology:
Microscopic pathology:
IHC might be positive for S100 |
Biopsy | ||||
Goblet cell carcinoid | + | +/- | + |
|
+/- | + |
|
+/- |
|
Unfortunately, compared to the other carcinoid tumors of appendix, GCC is more aggressive and patients with GCC generally present at higher stages. Hence, in addition to the above mentioned general findings for appendix cancers, imaging studies should look for evidences of peritoneal involvement, bone metastasis, lymphadenopathy, and metastatic lesions in ovaries and/or prostate. |
Gross pathology:
Microscopic appearance:
|
Biopsy | ||||
Appendix Mucocele | Mucosal hyperlasia | - | - | - |
|
- | +/- | N/A | - | N/A |
|
|Rounded right iliac fossa mass
|
|
N/A | Similar to hyperplastic colon polyp | Biopsy |
Simple or retention cyst | - | - | - | - | +/- | - | - | N/A | Degenerative epithelial changes because of obstruction | Biopsy | ||||||
Mucinous cystadenomas | +/- | +/- | +/-Diarrhea
+/-Constipation |
|
+/- | +/- | If develop pseudomyxoma peritonei:
|
- |
|
|
Biopsy | |||||
Mucinous cystadenocarcinomas | +/- | +/- | +/-Diarrhea
+/-Constipation |
+/- | +/- | - | - |
|
|
Biopsy | ||||||
Ovarian cancer | +/- | +/- | +/-Constipation |
|
+ | +/- |
|
- |
|
|
|
|
N/A | Depends on the tumor type. You may find the details here. | Biopsy | |
Colorectal cancer | +/- | +/- | +/-Diarrhea
+ Constipation |
|
+ | +/- | Colonoscopy
Adenocarcinoma
Carcinoids
|
-/+(Carcinoid tumors) |
|
luminal narrowing, intestinal wall thickening,intussusception, bowel obstruction, hepatic metastases, intestinal perforation,enlarged lymph nodes |
|
Generally not recommended: may evaluate liver metastasis or presence of fluid in abdominal cavity, but it is neither sensitive nor specific. | PET scan, Endoscopy, Colonoscopy,
Barium enema |
|
Biopsy | |
Pseudomyxoma peritonei | + | + | +/-Diarrhea
+/-Constipation |
Bloating | - | + | Ascites
Shifting dullness |
- |
|
|
Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele. |
|
18F-FDG PET scan |
|
| |
Carcinoid syndrome | -/+ | - | Diarrhea | Flushing
Palpitation Dyspnea |
- | - |
|
+ | Depends on the tumor type:
|
Depends on the primary tumor location and type | Depends on the primary tumor location and type | Depends on the primary tumor location and type |
|
|
Biopsy from the tumor is the gold standard method of diagnosis, meanwhile
5-HIAA (5-hydroxyindoleacetic acid) is the most specific marker of carcinoid tumors | |
Appendicitis 3 | Periumbelical, RLQ | - | +/- Diarrhea
+ Constipation |
Nausea & vomiting,decreased appetite
Anorexia |
+/- | + |
|
- |
|
Appendiceal wall thickening /perforation
peri-appendiceal inflammation, fluid accumulation,fat stranding |
Increased fluid signal on T2 weighted sequence | Evidences of inflammation
|
Tc-99m labeled anti-CD15 antibodies | Evidences of inflammation | A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history |
1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.
2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.
3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.
*Abbreviations: RLQ: Right Lower Quadrant, AFP:Alpha Fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA 125: Cancer antigen 125